Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025BJU InternationalOpen Access

Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMichiel VlamingWKWouter KooleRMR. Jeroen A. van Moorselaar

Discussion

Loading...

Member takes

Overview

A prospective cohort study assessed germline pathogenic variants in genes linked to breast cancer, revealing critical prevalence rates in metastatic prostate cancer.

Key Points

  • About 5.9% of patients with metastatic prostate cancer carried germline pathogenic variants, indicating a significant prevalence.
  • Genetic testing revealed that variants in CHEK2, ATM, and BRCA2 were much more frequent than in the general population, with odds ratios of 2.4, 2.8, and 3.1.
  • Factors such as family history of breast cancer and Jewish ancestry were linked to a higher likelihood of germline pathogenic variants in these patients.
  • This research highlights the importance of germline testing in identifying at-risk individuals for better health management in metastatic prostate cancer.

Cite This Study

Vlaming et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d64781776https://doi.org/10.1111/bju.16916
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identifying and Characterizing the Germinal Genetic Landscape of Men with Prostate Cancer—A Real‐Life Retrospective Multi‐Centered Study2025
  2. 2Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?2025 · 1 citations
  3. 3Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients2025
  4. 4Prevalence and impact of germline mutations in pancreatic ductal adenocarcinoma2026
  5. 5Genetic landscape of Pakistani familial breast cancer patients using multigene panel testing2025